Structure Therapeutics selects lead oral amylin agonist ACCG-2671 for obesity; Phase 1 start by end-2025

Structure Therapeutics Inc.

ACCG-2671 is a Dual Amylin and Calcitonin Receptor Agonist (DACRA) designed for once-daily oral dosing.
Preclinical data show cagrilintide-like efficacy with potent target engagement and favorable safety profile.
Phase 1 clinical development expected to begin by year end 2025.
Company believes ACCG-2671 could serve as backbone therapy for fixed-dose oral combinations with GLP-1 candidate GSBR-1290.
Structure is developing a series of amylin-based candidates using its GPCR structure-based drug discovery platform.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.